Patents Assigned to Glysens, Incorporated
  • Patent number: 11278668
    Abstract: Apparatus and methods for error modeling and correction in one or both of (i) a partially or fully implanted or non-implanted medicant delivery mechanism (such as a pump), and (ii) implanted physiologic parameter sensor. In one exemplary embodiment, the apparatus and methods employ a training mode of operation, whereby the apparatus conducts “machine learning” to model one or more errors (e.g., unmodeled variable system errors) associated with the medicant dose calculation process, and (ii) generation of a medicant delivery operational model (based at least in part on data collected/received in the training mode), which is applied to correct or compensate for the errors during normal operation of the sensor and pump system. This enhances accuracy of medicant delivery, such as over the lifetime of an implanted pump at a single implantation site, or during multiple relocations of a transcutaneously implanted pump), and enables “personalization” of the pump to each user.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: March 22, 2022
    Assignee: GlySens Incorporated
    Inventors: Piyush Gupta, Joseph Lucisano
  • Patent number: 11255839
    Abstract: Apparatus and methods for response modeling and correction of signals associated with a parameter sensor. In one exemplary embodiment, the parameter sensor is configured to measure a physiologic analyte of a living being (e.g., blood glucose), and the apparatus and methods employ a mathematical transformation of two or more sensing elements (electrodes) of the sensor in order to compensate for temporal response differences or “mismatch.” This compensation enables the calculated blood analyte level, which results from processing of the signals of the two or more sensing electrodes, to be more accurate than calculations made without such compensation. In one variant, the parameter signals are generated, and compensation processing conducted, autonomously via a common implanted sensor platform.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: February 22, 2022
    Assignee: GLYSENS INCORPORATED
    Inventors: Piyush Gupta, Joseph Lucisano
  • Patent number: 10736553
    Abstract: Enzymatic and non-enzymatic detectors and associated membrane apparatus, and methods of use, such as within a fully implantable sensor apparatus. In one embodiment, detector performance is controlled through selective use of membrane configurations and enzyme region shapes, which enable accurate detection of blood glucose level within the solid tissue of the living host for extended periods of time. Isolation between the host's tissue and the underlying enzymes and reaction byproducts used in the detectors is also advantageously maintained in one embodiment via use of a non-enzyme containing permeable membrane formed of e.g., a biocompatible crosslinked protein-based material. Control of response range and/or rate in some embodiments also permits customization of sensor elements. In one variant, heterogeneous detector elements are used to, e.g., accommodate a wider range of blood glucose concentration within the host.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: August 11, 2020
    Assignee: GlySens Incorporated
    Inventors: Joseph Lucisano, Bahman Javidi, Lev Kurbanyan, Joe Lin, Timothy Routh, Bradley Walker
  • Patent number: 10660550
    Abstract: Implantable sensor apparatus and methods of implantation. In one embodiment, a fully implantable, biocompatible sensor is disposed within a cavity or pocket formed within a living being, such that the sensor remains in a desired orientation and placement so as to enhance the performance of the sensor, and mitigate the effects of one or more factors potentially deleterious to the operation of the sensor and the host being. In one implementation, the sensor comprises an implantable biocompatible oxygen-based glucose sensor which is implanted deep within the being's torso tissue proximate the extant fascia, and oriented such that an active detector aspect of the device faces away from the being's skin surface. In one variant, the deep placement, orientation, and construction of the sensor itself cooperate to enhance the performance of the sensor, especially over extended periods of time, with little need for external calibration.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: May 26, 2020
    Assignee: GLYSENS INCORPORATED
    Inventors: Joseph Lucisano, Jonathan Wilensky, Robert Engler
  • Patent number: 10638962
    Abstract: Biocompatible implantable sensor apparatus and methods of implantation and use. In one embodiment, the sensor apparatus is an oxygen-based glucose sensor having biocompatibility features that mitigate the host tissue response. In one variant, these features include use of a non-enzymatic membrane over each of the individual analyte detectors so as to preclude contact of the surrounding tissue with the underlying enzyme or other matrix, and mitigate vascularization, and insulation of the various electrodes and associated electrolytic processes of the sensor from the surrounding tissue. In one implementation, the sensor region of the implanted apparatus is configured to interlock or imprint the surrounding tissue so as to promote a high degree of glucose molecule diffusion into the individual detectors, and a constant and predictable sensor to blood vessel interface, yet preclude the tissue from bonding to the sensor, especially over extended periods of implant.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: May 5, 2020
    Assignee: GlySens Incorporated
    Inventors: Joseph Lucisano, Timothy Routh, Joe Lin
  • Patent number: 10638979
    Abstract: Apparatus and methods for error modeling and correction in a blood analyte sensor or system. In one exemplary embodiment, the apparatus employs: (i) a training mode of operation, whereby the apparatus conducts “machine learning” to model one or more errors (e.g., unmodeled variable system errors) associated with the blood analyte measurement process, and (ii) generation of an operational model (based at least in part on data collected/received in the training mode), which is applied to correct or compensate for the errors during normal operation and collection of blood analyte data. This enhances device signal stability and accuracy over extended periods, thereby enabling among other things extended periods of blood analyte sensor implantation, and “personalization” of the sensor apparatus to each user receiving an implant. In one variant, the blood analyte is glucose, and the implanted sensor utilizes an oxygen-based molecular measurement principle.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: May 5, 2020
    Assignee: GlySens Incorporated
    Inventors: Piyush Gupta, Joseph Lucisano
  • Patent number: 10561353
    Abstract: Enzymatic and non-enzymatic detectors and associated membrane apparatus, and methods of use, such as within a fully implantable sensor apparatus. In one embodiment, detector performance is controlled through selective use of membrane configurations and enzyme region shapes, which enable accurate detection of blood glucose level within the solid tissue of the living host for extended periods of time. Isolation between the host's tissue and the underlying enzymes and reaction byproducts used in the detectors is also advantageously maintained in one embodiment via use of a non-enzyme containing permeable membrane formed of e.g., a biocompatible crosslinked protein-based material. Control of response range and/or rate in some embodiments also permits customization of sensor elements. In one variant, heterogeneous detector elements are used to, e.g., accommodate a wider range of blood glucose concentration within the host.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: February 18, 2020
    Assignee: GLYSENS INCORPORATED
    Inventors: Joseph Lucisano, Bahman Javidi, Lev Kurbanyan, Joe Lin, Timothy Routh, Bradley Walker
  • Patent number: 10561351
    Abstract: A tissue-implantable sensor for measurement of solutes in fluids and gases, such as oxygen and glucose, is provided. The sensor includes: i) a detector array including at least one detector; ii) a telemetry transmission portal; iii) an electrical power source; and iv) circuitry electrically connected to the detector array including signal processing means for determining an analyte level, such as glucose level, in a body fluid contacting the detectors. The sensor components are disposed in a hermetically sealed housing having a size and shape suitable for comfortable, safe, and unobtrusive subcutaneous implantation allowing for in vivo detection and long term monitoring of tissue glucose concentrations by wireless telemetry.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: February 18, 2020
    Assignee: GLYSENS INCORPORATED
    Inventors: Joseph Y. Lucisano, Mark B. Catlin, William J. Choi, Payton C. Chu, Joe T. Lin, Timothy L. Routh, Thomas G. Wallner
  • Patent number: 10041897
    Abstract: At least one conductor is formed at a preselected location on a substrate made of a first insulating material having a high temperature resistance. The conductor is made from a solidified electrically conductive thick film material. A coating made of a second insulating material is formed over the substrate to hermetically seal at least a portion of the conductor. An exposed distal region of the conductor provides a detection electrode. The conductor has a reduced porosity that inhibits migration of fluid or constituents thereof through the conductor.
    Type: Grant
    Filed: February 9, 2011
    Date of Patent: August 7, 2018
    Assignee: Glysens, Incorporated, a California Corporation
    Inventors: Joseph Y. Lucisano, Mark B. Catlin
  • Patent number: 7894870
    Abstract: At least one conductor is formed at a preselected location on a substrate made of a first insulating material having a high temperature resistance. The conductor is made from a solidified electrically conductive thick film material. A coating made of a second insulating material is formed over the substrate to hermetically seal at least a portion of the conductor. An exposed distal region of the conductor provides a detection electrode. The conductor has a reduced porosity that inhibits migration of fluid or constituents thereof through the conductor.
    Type: Grant
    Filed: August 23, 2004
    Date of Patent: February 22, 2011
    Assignee: Glysens, Incorporated
    Inventors: Joseph Y. Lucisano, Mark B. Catlin